Table 1 Characteristics of included studies
First author, year (country) | Sample size (IC/IV group) | Follow-up duration, months | Symptom onseta, hours | Thrombectomy | Stenting (DES) | P2Y12 inhibitors | GP-IIb/IIIa inhibitors | IC bolus doseb | Maintenance IV infusion |
|---|---|---|---|---|---|---|---|---|---|
Bellandi, 2004 (Italy) [23] | 22/23 | 1 | ≤ 6 | NA | 100% (NA) | TP | Abciximab | Standard | Y |
Thiele, 2008 (Germany) [24] | 77/77 | 1 | ≤ 12 | NA | Almost all (NA) | C | Abciximab | Standard | Y |
Dominguez-Rodriguez, 2009 (Spain) [25] | 25/25 | 1 | ≤ 6 | 100% | 100% (NA) | C | Abciximab | Standard | Y |
Bertrand, 2010 (Canada) [26] | 53/52 | 12 | ≤ 6 | 42% | NA (NA) | C | Abciximab | Standard | Y |
Gu, 2010 (Netherlands) [27] | 271/263 | 1 | ≤ 12 | 98% | 95% (NA) | C or P | Abciximab | Standard | N |
Eitel, 2011 (Germany) [28] | 77/77 | 6 | ≤ 12 | NA | NA (NA) | C | Abciximab | Standard | Y |
Iversen, 2011 [30 days] (Denmark) [29] | 185/170 | 1 | ≤ 12 | 0% | 95% (80%) | C | Abciximab | Standard | Y |
Iversen, 2011 [1 year] (Denmark) [30] | 185/170 | 12 | ≤ 12 | 0% | 95% (80%) | C | Abciximab | Standard | Y |
Kirma, 2012 (Turkey) [37] | 25/24 | 6 | ≤ 12 | NA | 100% (NA) | C | Tirofiban | Standard | Y (IV group only) |
Thiele, 2012 (Germany) [6] | 1032/1033 | 3 | ≤ 12 | 20% | Almost all (NA) | C or P | Abciximab | Standard | Y |
Desch, 2013 (Germany) [31] | 925/921 | 12 | ≤ 12 | 20% | Almost all (NA) | C or P | Abciximab | Standard | Y |
Eitel, 2013 (Germany) [32] | 394/401 | 12 | ≤ 12 | 24% | 98% (42%) | C or P | Abciximab | Standard | Y |
Namazi, 2013 (Iran) [39] | 20/20 | Until discharge | ≤ 12 | 68% | 100% (65%) | C | Abciximab (IC group) Eptifibatide (IV group) | Standard | N |
Pellicori, 2013 (Italy) [40] | 38/39 | 12 | ≤ 12 | 0% | 100% (NA) | C | Abciximab or eptifibatide | Abciximab: Standard Eptifibatide: Low | Y |
Secco, 2014 (Italy) [33] | 47/42 | 6 | ≤ 12 | 25% | NA | C | Abciximab | Standard | N |
Esfandi, 2016 (Iran) [35] | 36/38 | Until discharge | NA | NA | 100% (100%) | C | Eptifibatide | Standard | Y |
Sanati, 2017 (Iran) [7] | 32/32 | Until discharge | ≤ 12 | NA | NA (10%) | C | Eptifibatide | Standard | Y |
Bedjaoui, 2019 (Algeria) [34] | 78/82 | 6 | ≤ 12 | 82% | 96% (NA) | C | Abciximab | Standard | Y |
Nab, 2019 (Egypt) [36] | 50/50 | 1 | ≤ 12 | 92% | 100% (0%) | C | Eptifibatide | Standard | Y |
Ma, 2020 (China) [8] | 106/102 | 12 | ≤ 12 | NA | 100% (NA) | C | Tirofiban | Low | Y |
Tang, 2022 [DM] (China) [38] | 100/100 | 15 days | ≤ 2 | NA | NA | NA | Tirofiban | Low | Y |
Tang, 2022 (China) [16] | 90/90 | 6 | ≤ 12 | 26% | Almost all (NA) | TG | Tirofiban | Low | Y |